Lung Cancer Patient Respond to Erlotinib Following Cetuximab Therapy, Study Suggests


August 3, 2009

ScienceDaily

Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported at the annual meeting of the International Association for the Study of Lung Cancer.

Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth factor receptor (EGFR) and the assumption has been that once a patient progresses on one EGFR inhibitor they will not respond to another EGFR inhibitor. The new data suggests that may not be the case... Read More